Halozyme Therapeutics (NASDAQ:HALO) Upgraded at Zacks Research

Halozyme Therapeutics (NASDAQ:HALO) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

A number of other equities research analysts have also issued reports on HALO. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.50.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $116.82 on Tuesday. The stock has a 50-day moving average price of $107.97 and a 200 day moving average price of $84.24. The stock has a market capitalization of $13.26 billion, a P/E ratio of 34.87, a P/E/G ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics has a 12-month low of $61.22 and a 12-month high of $119.21. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter last year, the company earned $1.54 EPS. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts forecast that Halozyme Therapeutics will post 8.31 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $82,482,605.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 125,852 shares of company stock valued at $13,538,046. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $28,000. Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $30,000. CoreCap Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 150 shares during the period. Finally, Caitlin John LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $44,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.